Dermatitis Clinical Trial
Official title:
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents.
This study includes a screening period of up to 35 days, a 16-week double-blind treatment period (Period A), and a 36-week double-blind treatment period (Period B). Participants who meet eligibility criteria will be randomized at Baseline in a 2:2:1 ratio to one of 3 treatment groups: (1) risankizumab 150 mg, (2) risankizumab 300 mg, or (3) matching placebo. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]) and geographic region (Japan versus rest of world). At Week 16, participants in the placebo group will be re-randomized in a 1:1 ratio to receive either risankizumab 150 mg or 300 mg for the remainder of the study. Participants originally randomized to the risankizumab 150 mg or 300 mg arms will stay on their previously-assigned treatment through the end of the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
| Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
| Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
| Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 | |
| Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
| Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
| Withdrawn |
NCT04154033 -
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
|
Phase 2 | |
| Completed |
NCT02979210 -
Infant Fecal Insult Study
|
N/A | |
| Completed |
NCT02615912 -
A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants
|
N/A | |
| Withdrawn |
NCT01125761 -
Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis
|
Phase 3 | |
| Withdrawn |
NCT00746382 -
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
|
Phase 2 | |
| Terminated |
NCT00176956 -
Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients
|
Phase 3 | |
| Completed |
NCT05001139 -
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
|
N/A | |
| Completed |
NCT00801502 -
Salmon in Pregnancy Study
|
N/A | |
| Completed |
NCT00005781 -
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
|
N/A | |
| Completed |
NCT05324618 -
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
|
Phase 4 | |
| Completed |
NCT04826471 -
Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam
|
N/A | |
| Recruiting |
NCT06436183 -
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 |